ID   MK09_HUMAN              Reviewed;         424 AA.
AC   P45984; A8K0S3; B5BU66; B5M0B4; D3DWQ8; D3DWQ9; Q15708; Q15710;
AC   Q15711; Q8N5C5;
DT   01-NOV-1995, integrated into UniProtKB/Swiss-Prot.
DT   24-JAN-2006, sequence version 2.
DT   10-MAY-2017, entry version 188.
DE   RecName: Full=Mitogen-activated protein kinase 9;
DE            Short=MAP kinase 9;
DE            Short=MAPK 9;
DE            EC=2.7.11.24;
DE   AltName: Full=JNK-55;
DE   AltName: Full=Stress-activated protein kinase 1a;
DE            Short=SAPK1a;
DE   AltName: Full=Stress-activated protein kinase JNK2;
DE   AltName: Full=c-Jun N-terminal kinase 2;
GN   Name=MAPK9; Synonyms=JNK2, PRKM9, SAPK1A;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA].
RX   PubMed=7969172; DOI=10.1128/MCB.14.12.8376;
RA   Sluss H.K., Barrett T., Derijard B., Davis R.J.;
RT   "Signal transduction by tumor necrosis factor mediated by JNK protein
RT   kinases.";
RL   Mol. Cell. Biol. 14:8376-8384(1994).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA].
RX   PubMed=8001819; DOI=10.1101/gad.8.24.2996;
RA   Kallunki T., Su B., Tsigelny I., Sluss H.K., Derijard B., Moore G.,
RA   Davis R., Karin M.;
RT   "JNK2 contains a specificity-determining region responsible for
RT   efficient c-Jun binding and phosphorylation.";
RL   Genes Dev. 8:2996-3007(1994).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [MRNA], AND ALTERNATIVE SPLICING.
RC   TISSUE=Brain;
RX   PubMed=8654373;
RA   Gupta S., Barrett T., Whitmarsh A.J., Cavanagh J., Sluss H.K.,
RA   Derijard B., Davis R.J.;
RT   "Selective interaction of JNK protein kinase isoforms with
RT   transcription factors.";
RL   EMBO J. 15:2760-2770(1996).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 5).
RX   PubMed=21110917; DOI=10.5483/BMBRep.2010.43.11.738;
RA   Wang P., Xiong Y., Ma C., Shi T., Ma D.;
RT   "Molecular cloning and characterization of novel human JNK2 (MAPK9)
RT   transcript variants that show different stimulation activities on AP-
RT   1.";
RL   BMB Rep. 43:738-743(2010).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RA   Halleck A., Ebert L., Mkoundinya M., Schick M., Eisenstein S.,
RA   Neubert P., Kstrang K., Schatten R., Shen B., Henze S., Mar W.,
RA   Korn B., Zuo D., Hu Y., LaBaer J.;
RT   "Cloning of human full open reading frames in Gateway(TM) system entry
RT   vector (pDONR201).";
RL   Submitted (JUN-2004) to the EMBL/GenBank/DDBJ databases.
RN   [6]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM BETA-2).
RC   TISSUE=Amygdala;
RX   PubMed=14702039; DOI=10.1038/ng1285;
RA   Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R.,
RA   Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H.,
RA   Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S.,
RA   Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K.,
RA   Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A.,
RA   Sudo H., Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M.,
RA   Takahashi M., Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y.,
RA   Abe K., Kamihara K., Katsuta N., Sato K., Tanikawa M., Yamazaki M.,
RA   Ninomiya K., Ishibashi T., Yamashita H., Murakawa K., Fujimori K.,
RA   Tanai H., Kimata M., Watanabe M., Hiraoka S., Chiba Y., Ishida S.,
RA   Ono Y., Takiguchi S., Watanabe S., Yosida M., Hotuta T., Kusano J.,
RA   Kanehori K., Takahashi-Fujii A., Hara H., Tanase T.-O., Nomura Y.,
RA   Togiya S., Komai F., Hara R., Takeuchi K., Arita M., Imose N.,
RA   Musashino K., Yuuki H., Oshima A., Sasaki N., Aotsuka S.,
RA   Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S.,
RA   Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O.,
RA   Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H.,
RA   Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B.,
RA   Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y.,
RA   Fujimori Y., Komiyama M., Tashiro H., Tanigami A., Fujiwara T.,
RA   Ono T., Yamada K., Fujii Y., Ozaki K., Hirao M., Ohmori Y.,
RA   Kawabata A., Hikiji T., Kobatake N., Inagaki H., Ikema Y., Okamoto S.,
RA   Okitani R., Kawakami T., Noguchi S., Itoh T., Shigeta K., Senba T.,
RA   Matsumura K., Nakajima Y., Mizuno T., Morinaga M., Sasaki M.,
RA   Togashi T., Oyama M., Hata H., Watanabe M., Komatsu T.,
RA   Mizushima-Sugano J., Satoh T., Shirai Y., Takahashi Y., Nakagawa K.,
RA   Okumura K., Nagase T., Nomura N., Kikuchi H., Masuho Y., Yamashita R.,
RA   Nakai K., Yada T., Nakamura Y., Ohara O., Isogai T., Sugano S.;
RT   "Complete sequencing and characterization of 21,243 full-length human
RT   cDNAs.";
RL   Nat. Genet. 36:40-45(2004).
RN   [7]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA], AND VARIANT ALA-268.
RG   NIEHS SNPs program;
RL   Submitted (MAY-2005) to the EMBL/GenBank/DDBJ databases.
RN   [8]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM ALPHA-2).
RX   PubMed=19054851; DOI=10.1038/nmeth.1273;
RA   Goshima N., Kawamura Y., Fukumoto A., Miura A., Honma R., Satoh R.,
RA   Wakamatsu A., Yamamoto J., Kimura K., Nishikawa T., Andoh T., Iida Y.,
RA   Ishikawa K., Ito E., Kagawa N., Kaminaga C., Kanehori K., Kawakami B.,
RA   Kenmochi K., Kimura R., Kobayashi M., Kuroita T., Kuwayama H.,
RA   Maruyama Y., Matsuo K., Minami K., Mitsubori M., Mori M.,
RA   Morishita R., Murase A., Nishikawa A., Nishikawa S., Okamoto T.,
RA   Sakagami N., Sakamoto Y., Sasaki Y., Seki T., Sono S., Sugiyama A.,
RA   Sumiya T., Takayama T., Takayama Y., Takeda H., Togashi T., Yahata K.,
RA   Yamada H., Yanagisawa Y., Endo Y., Imamoto F., Kisu Y., Tanaka S.,
RA   Isogai T., Imai J., Watanabe S., Nomura N.;
RT   "Human protein factory for converting the transcriptome into an in
RT   vitro-expressed proteome.";
RL   Nat. Methods 5:1011-1017(2008).
RN   [9]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=15372022; DOI=10.1038/nature02919;
RA   Schmutz J., Martin J., Terry A., Couronne O., Grimwood J., Lowry S.,
RA   Gordon L.A., Scott D., Xie G., Huang W., Hellsten U., Tran-Gyamfi M.,
RA   She X., Prabhakar S., Aerts A., Altherr M., Bajorek E., Black S.,
RA   Branscomb E., Caoile C., Challacombe J.F., Chan Y.M., Denys M.,
RA   Detter J.C., Escobar J., Flowers D., Fotopulos D., Glavina T.,
RA   Gomez M., Gonzales E., Goodstein D., Grigoriev I., Groza M.,
RA   Hammon N., Hawkins T., Haydu L., Israni S., Jett J., Kadner K.,
RA   Kimball H., Kobayashi A., Lopez F., Lou Y., Martinez D., Medina C.,
RA   Morgan J., Nandkeshwar R., Noonan J.P., Pitluck S., Pollard M.,
RA   Predki P., Priest J., Ramirez L., Retterer J., Rodriguez A.,
RA   Rogers S., Salamov A., Salazar A., Thayer N., Tice H., Tsai M.,
RA   Ustaszewska A., Vo N., Wheeler J., Wu K., Yang J., Dickson M.,
RA   Cheng J.-F., Eichler E.E., Olsen A., Pennacchio L.A., Rokhsar D.S.,
RA   Richardson P., Lucas S.M., Myers R.M., Rubin E.M.;
RT   "The DNA sequence and comparative analysis of human chromosome 5.";
RL   Nature 431:268-274(2004).
RN   [10]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RA   Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L.,
RA   Mobarry C.M., Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R.,
RA   Flanigan M.J., Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V.,
RA   Hannenhalli S., Turner R., Yooseph S., Lu F., Nusskern D.R.,
RA   Shue B.C., Zheng X.H., Zhong F., Delcher A.L., Huson D.H.,
RA   Kravitz S.A., Mouchard L., Reinert K., Remington K.A., Clark A.G.,
RA   Waterman M.S., Eichler E.E., Adams M.D., Hunkapiller M.W., Myers E.W.,
RA   Venter J.C.;
RL   Submitted (SEP-2005) to the EMBL/GenBank/DDBJ databases.
RN   [11]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RC   TISSUE=Skin;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA
RT   project: the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [12]
RP   INTERACTION WITH ATF7, AND FUNCTION.
RX   PubMed=10376527; DOI=10.1038/sj.onc.1202723;
RA   De Graeve F., Bahr A., Sabapathy K.T., Hauss C., Wagner E.F.,
RA   Kedinger C., Chatton B.;
RT   "Role of the ATFa/JNK2 complex in Jun activation.";
RL   Oncogene 18:3491-3500(1999).
RN   [13]
RP   PHOSPHORYLATION AT THR-183 AND TYR-185, REGULATION BY MAP2K4 AND
RP   MAP2K7, AND COFACTOR.
RX   PubMed=11062067; DOI=10.1042/bj3520145;
RA   Fleming Y., Armstrong C.G., Morrice N., Paterson A., Goedert M.,
RA   Cohen P.;
RT   "Synergistic activation of stress-activated protein kinase 1/c-Jun N-
RT   terminal kinase (SAPK1/JNK) isoforms by mitogen-activated protein
RT   kinase kinase 4 (MKK4) and MKK7.";
RL   Biochem. J. 352:145-154(2000).
RN   [14]
RP   INTERACTION WITH SPAG9.
RX   PubMed=15693750; DOI=10.1042/BJ20041577;
RA   Jagadish N., Rana R., Selvi R., Mishra D., Garg M., Yadav S.,
RA   Herr J.C., Okumura K., Hasegawa A., Koyama K., Suri A.;
RT   "Characterization of a novel human sperm-associated antigen 9 (SPAG9)
RT   having structural homology with c-Jun N-terminal kinase-interacting
RT   protein.";
RL   Biochem. J. 389:73-82(2005).
RN   [15]
RP   FUNCTION IN PHOSPHORYLATION OF RRN3.
RX   PubMed=15805466; DOI=10.1101/gad.333205;
RA   Mayer C., Bierhoff H., Grummt I.;
RT   "The nucleolus as a stress sensor: JNK2 inactivates the transcription
RT   factor TIF-IA and down-regulates rRNA synthesis.";
RL   Genes Dev. 19:933-941(2005).
RN   [16]
RP   INTERACTION WITH NFATC4.
RX   PubMed=17875713; DOI=10.1158/0008-5472.CAN-06-4788;
RA   Yao K., Cho Y.-Y., Bergen H.R. III, Madden B.J., Choi B.Y., Ma W.-Y.,
RA   Bode A.M., Dong Z.;
RT   "Nuclear factor of activated T3 is a negative regulator of Ras-JNK1/2-
RT   AP-1 induced cell transformation.";
RL   Cancer Res. 67:8725-8735(2007).
RN   [17]
RP   INTERACTION WITH BCL10.
RX   PubMed=17189706; DOI=10.1016/j.immuni.2006.11.008;
RA   Blonska M., Pappu B.P., Matsumoto R., Li H., Su B., Wang D., Lin X.;
RT   "The CARMA1-Bcl10 signaling complex selectively regulates JNK2 kinase
RT   in the T cell receptor-signaling pathway.";
RL   Immunity 26:55-66(2007).
RN   [18]
RP   FUNCTION IN PHOSPHORYLATION OF TP53.
RX   PubMed=17525747; DOI=10.1038/sj.onc.1210526;
RA   Oleinik N.V., Krupenko N.I., Krupenko S.A.;
RT   "Cooperation between JNK1 and JNK2 in activation of p53 apoptotic
RT   pathway.";
RL   Oncogene 26:7222-7230(2007).
RN   [19]
RP   REVIEW ON FUNCTION.
RX   PubMed=19290929; DOI=10.1111/j.1600-065X.2008.00749.x;
RA   Blonska M., Lin X.;
RT   "CARMA1-mediated NF-kappaB and JNK activation in lymphocytes.";
RL   Immunol. Rev. 228:199-211(2009).
RN   [20]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=19369195; DOI=10.1074/mcp.M800588-MCP200;
RA   Oppermann F.S., Gnad F., Olsen J.V., Hornberger R., Greff Z., Keri G.,
RA   Mann M., Daub H.;
RT   "Large-scale proteomics analysis of the human kinome.";
RL   Mol. Cell. Proteomics 8:1751-1764(2009).
RN   [21]
RP   FUNCTION, SUBCELLULAR LOCATION, AND INTERACTION WITH CTNNB1.
RX   PubMed=19675674; DOI=10.1371/journal.pone.0006640;
RA   Hu D., Bi X., Fang W., Han A., Yang W.;
RT   "GSK3beta is involved in JNK2-mediated beta-catenin inhibition.";
RL   PLoS ONE 4:E6640-E6640(2009).
RN   [22]
RP   FUNCTION.
RX   PubMed=20595622; DOI=10.1152/ajpgi.00265.2010;
RA   Samak G., Suzuki T., Bhargava A., Rao R.K.;
RT   "c-Jun NH2-terminal kinase-2 mediates osmotic stress-induced tight
RT   junction disruption in the intestinal epithelium.";
RL   Am. J. Physiol. 299:G572-G584(2010).
RN   [23]
RP   FUNCTION IN PHOSPHORYLATION OF YAP1.
RX   PubMed=21364637; DOI=10.1038/cddis.2010.7;
RA   Tomlinson V., Gudmundsdottir K., Luong P., Leung K.Y., Knebel A.,
RA   Basu S.;
RT   "JNK phosphorylates Yes-associated protein (YAP) to regulate
RT   apoptosis.";
RL   Cell Death Dis. 1:E29-E29(2010).
RN   [24]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=21269460; DOI=10.1186/1752-0509-5-17;
RA   Burkard T.R., Planyavsky M., Kaupe I., Breitwieser F.P.,
RA   Buerckstuemmer T., Bennett K.L., Superti-Furga G., Colinge J.;
RT   "Initial characterization of the human central proteome.";
RL   BMC Syst. Biol. 5:17-17(2011).
RN   [25]
RP   FUNCTION.
RX   PubMed=22441692; DOI=10.1038/embor.2012.37;
RA   Yoshitane H., Honma S., Imamura K., Nakajima H., Nishide S.Y., Ono D.,
RA   Kiyota H., Shinozaki N., Matsuki H., Wada N., Doi H., Hamada T.,
RA   Honma K., Fukada Y.;
RT   "JNK regulates the photic response of the mammalian circadian clock.";
RL   EMBO Rep. 13:455-461(2012).
RN   [26]
RP   X-RAY CRYSTALLOGRAPHY (2.14 ANGSTROMS) OF 7-362.
RX   PubMed=18801372; DOI=10.1016/j.jmb.2008.08.086;
RA   Shaw D., Wang S.M., Villasenor A.G., Tsing S., Walter D.,
RA   Browner M.F., Barnett J., Kuglstatter A.;
RT   "The crystal structure of JNK2 reveals conformational flexibility in
RT   the MAP kinase insert and indicates its involvement in the regulation
RT   of catalytic activity.";
RL   J. Mol. Biol. 383:885-893(2008).
RN   [27]
RP   VARIANTS [LARGE SCALE ANALYSIS] MET-13; ASN-56; THR-246 AND ILE-366.
RX   PubMed=17344846; DOI=10.1038/nature05610;
RA   Greenman C., Stephens P., Smith R., Dalgliesh G.L., Hunter C.,
RA   Bignell G., Davies H., Teague J., Butler A., Stevens C., Edkins S.,
RA   O'Meara S., Vastrik I., Schmidt E.E., Avis T., Barthorpe S.,
RA   Bhamra G., Buck G., Choudhury B., Clements J., Cole J., Dicks E.,
RA   Forbes S., Gray K., Halliday K., Harrison R., Hills K., Hinton J.,
RA   Jenkinson A., Jones D., Menzies A., Mironenko T., Perry J., Raine K.,
RA   Richardson D., Shepherd R., Small A., Tofts C., Varian J., Webb T.,
RA   West S., Widaa S., Yates A., Cahill D.P., Louis D.N., Goldstraw P.,
RA   Nicholson A.G., Brasseur F., Looijenga L., Weber B.L., Chiew Y.-E.,
RA   DeFazio A., Greaves M.F., Green A.R., Campbell P., Birney E.,
RA   Easton D.F., Chenevix-Trench G., Tan M.-H., Khoo S.K., Teh B.T.,
RA   Yuen S.T., Leung S.Y., Wooster R., Futreal P.A., Stratton M.R.;
RT   "Patterns of somatic mutation in human cancer genomes.";
RL   Nature 446:153-158(2007).
RN   [28]
RP   INTERACTION WITH MAPKBP1.
RX   PubMed=28089251; DOI=10.1016/j.ajhg.2016.12.011;
RA   Macia M.S., Halbritter J., Delous M., Bredrup C., Gutter A.,
RA   Filhol E., Mellgren A.E., Leh S., Bizet A., Braun D.A., Gee H.Y.,
RA   Silbermann F., Henry C., Krug P., Bole-Feysot C., Nitschke P.,
RA   Joly D., Nicoud P., Paget A., Haugland H., Brackmann D., Ahmet N.,
RA   Sandford R., Cengiz N., Knappskog P.M., Boman H., Linghu B., Yang F.,
RA   Oakeley E.J., Saint Mezard P., Sailer A.W., Johansson S., Roedahl E.,
RA   Saunier S., Hildebrandt F., Benmerah A.;
RT   "Mutations in MAPKBP1 cause juvenile or late-onset cilia-independent
RT   nephronophthisis.";
RL   Am. J. Hum. Genet. 100:323-333(2017).
RN   [29]
RP   ERRATUM.
RX   PubMed=28157543; DOI=10.1016/j.ajhg.2017.01.025;
RA   Macia M.S., Halbritter J., Delous M., Bredrup C., Gutter A.,
RA   Filhol E., Mellgren A.E., Leh S., Bizet A., Braun D.A., Gee H.Y.,
RA   Silbermann F., Henry C., Krug P., Bole-Feysot C., Nitschke P.,
RA   Joly D., Nicoud P., Paget A., Haugland H., Brackmann D., Ahmet N.,
RA   Sandford R., Cengiz N., Knappskog P.M., Boman H., Linghu B., Yang F.,
RA   Oakeley E.J., Saint Mezard P., Sailer A.W., Johansson S., Roedahl E.,
RA   Saunier S., Hildebrandt F., Benmerah A.;
RL   Am. J. Hum. Genet. 100:372-372(2017).
CC   -!- FUNCTION: Serine/threonine-protein kinase involved in various
CC       processes such as cell proliferation, differentiation, migration,
CC       transformation and programmed cell death. Extracellular stimuli
CC       such as proinflammatory cytokines or physical stress stimulate the
CC       stress-activated protein kinase/c-Jun N-terminal kinase (SAP/JNK)
CC       signaling pathway. In this cascade, two dual specificity kinases
CC       MAP2K4/MKK4 and MAP2K7/MKK7 phosphorylate and activate MAPK9/JNK2.
CC       In turn, MAPK9/JNK2 phosphorylates a number of transcription
CC       factors, primarily components of AP-1 such as JUN and ATF2 and
CC       thus regulates AP-1 transcriptional activity. In response to
CC       oxidative or ribotoxic stresses, inhibits rRNA synthesis by
CC       phosphorylating and inactivating the RNA polymerase 1-specific
CC       transcription initiation factor RRN3. Promotes stressed cell
CC       apoptosis by phosphorylating key regulatory factors including TP53
CC       and YAP1. In T-cells, MAPK8 and MAPK9 are required for polarized
CC       differentiation of T-helper cells into Th1 cells. Upon T-cell
CC       receptor (TCR) stimulation, is activated by CARMA1, BCL10, MAP2K7
CC       and MAP3K7/TAK1 to regulate JUN protein levels. Plays an important
CC       role in the osmotic stress-induced epithelial tight-junctions
CC       disruption. When activated, promotes beta-catenin/CTNNB1
CC       degradation and inhibits the canonical Wnt signaling pathway.
CC       Participates also in neurite growth in spiral ganglion neurons.
CC       Phosphorylates the CLOCK-ARNTL/BMAL1 heterodimer and plays a role
CC       in the regulation of the circadian clock (PubMed:22441692).
CC       {ECO:0000269|PubMed:22441692}.
CC   -!- FUNCTION: MAPK9 isoforms display different binding patterns:
CC       alpha-1 and alpha-2 preferentially bind to JUN, whereas beta-1 and
CC       beta-2 bind to ATF2. However, there is no correlation between
CC       binding and phosphorylation, which is achieved at about the same
CC       efficiency by all isoforms. JUNB is not a substrate for JNK2
CC       alpha-2, and JUND binds only weakly to it.
CC   -!- CATALYTIC ACTIVITY: ATP + a protein = ADP + a phosphoprotein.
CC   -!- COFACTOR:
CC       Name=Mg(2+); Xref=ChEBI:CHEBI:18420;
CC         Evidence={ECO:0000269|PubMed:11062067};
CC   -!- ENZYME REGULATION: Activated by threonine and tyrosine
CC       phosphorylation by either of two dual specificity kinases, MAP2K4
CC       and MAP2K7. MAP2K4 shows a strong preference for Tyr-185 while
CC       MAP2K7 phosphorylates Tyr-183 preferentially. Inhibited by dual
CC       specificity phosphatases, such as DUSP1.
CC   -!- SUBUNIT: Interacts with MECOM (By similarity). Interacts with
CC       DCLK2 (By similarity). Binds to at least four scaffolding
CC       proteins, MAPK8IP1/JIP-1, MAPK8IP2/JIP-2, MAPK8IP3/JIP-3/JSAP1 and
CC       SPAG9/MAPK8IP4/JIP-4. These proteins also bind other components of
CC       the JNK signaling pathway (By similarity). Interacts with NFATC4
CC       (PubMed:17875713). Interacts with ATF7; the interaction does not
CC       phosphorylate ATF7 but acts as a docking site for ATF7-associated
CC       partners such as JUN (PubMed:10376527). Interacts with BCL10
CC       (PubMed:17189706). Interacts with CTNNB1 and GSK3B
CC       (PubMed:19675674). Interacts with MAPKBP1 (PubMed:28089251).
CC       {ECO:0000250|UniProtKB:P49186, ECO:0000250|UniProtKB:Q9WTU6,
CC       ECO:0000269|PubMed:10376527, ECO:0000269|PubMed:17189706,
CC       ECO:0000269|PubMed:17875713, ECO:0000269|PubMed:19675674,
CC       ECO:0000269|PubMed:28089251}.
CC   -!- INTERACTION:
CC       P49407:ARRB1; NbExp=7; IntAct=EBI-713568, EBI-743313;
CC       P32121:ARRB2; NbExp=7; IntAct=EBI-713568, EBI-714559;
CC       P15336:ATF2; NbExp=5; IntAct=EBI-713568, EBI-1170906;
CC       Q6P1W5:C1orf94; NbExp=3; IntAct=EBI-713568, EBI-946029;
CC       Q9C0F1:CEP44; NbExp=6; IntAct=EBI-713568, EBI-744115;
CC       Q13363-2:CTBP1; NbExp=3; IntAct=EBI-713568, EBI-10171858;
CC       Q5JST6:EFHC2; NbExp=5; IntAct=EBI-713568, EBI-2349927;
CC       Q96JM7:L3MBTL3; NbExp=3; IntAct=EBI-713568, EBI-2686809;
CC       Q8TBB1:LNX1; NbExp=5; IntAct=EBI-713568, EBI-739832;
CC       P50221:MEOX1; NbExp=5; IntAct=EBI-713568, EBI-2864512;
CC       Q15427:SF3B4; NbExp=6; IntAct=EBI-713568, EBI-348469;
CC       P34896:SHMT1; NbExp=5; IntAct=EBI-713568, EBI-715117;
CC       A2RU48:SMCO3; NbExp=3; IntAct=EBI-713568, EBI-10173195;
CC       P40763:STAT3; NbExp=3; IntAct=EBI-713586, EBI-518675;
CC       Q8IYF3:TEX11; NbExp=3; IntAct=EBI-713568, EBI-742397;
CC       O43379:WDR62; NbExp=4; IntAct=EBI-713568, EBI-714790;
CC   -!- SUBCELLULAR LOCATION: Cytoplasm {ECO:0000269|PubMed:19675674}.
CC       Nucleus {ECO:0000269|PubMed:19675674}.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=5;
CC       Name=Alpha-2;
CC         IsoId=P45984-1; Sequence=Displayed;
CC       Name=Alpha-1;
CC         IsoId=P45984-2; Sequence=VSP_004835;
CC       Name=Beta-1;
CC         IsoId=P45984-3; Sequence=VSP_004834, VSP_004835;
CC       Name=Beta-2;
CC         IsoId=P45984-4; Sequence=VSP_004834;
CC       Name=5;
CC         IsoId=P45984-5; Sequence=VSP_041908, VSP_041909;
CC   -!- DOMAIN: The TXY motif contains the threonine and tyrosine residues
CC       whose phosphorylation activates the MAP kinases.
CC   -!- PTM: Dually phosphorylated on Thr-183 and Tyr-185 by MAP2K7 and
CC       MAP2K4, which activates the enzyme. Autophosphorylated in vitro.
CC       {ECO:0000269|PubMed:11062067}.
CC   -!- SIMILARITY: Belongs to the protein kinase superfamily. CMGC
CC       Ser/Thr protein kinase family. MAP kinase subfamily.
CC       {ECO:0000305}.
CC   -!- WEB RESOURCE: Name=Atlas of Genetics and Cytogenetics in Oncology
CC       and Haematology;
CC       URL="http://atlasgeneticsoncology.org/Genes/JNK2ID426.html";
CC   -!- WEB RESOURCE: Name=NIEHS-SNPs;
CC       URL="http://egp.gs.washington.edu/data/mapk9/";
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; L31951; AAA56831.1; -; mRNA.
DR   EMBL; U09759; AAA74740.1; -; mRNA.
DR   EMBL; U34821; AAC50606.1; -; mRNA.
DR   EMBL; U35002; AAC50608.1; -; mRNA.
DR   EMBL; U35003; AAC50609.1; -; mRNA.
DR   EMBL; EU927388; ACH57450.1; -; mRNA.
DR   EMBL; CR536580; CAG38817.1; -; mRNA.
DR   EMBL; AK289638; BAF82327.1; -; mRNA.
DR   EMBL; DQ066599; AAY46156.1; -; Genomic_DNA.
DR   EMBL; AB451302; BAG70116.1; -; mRNA.
DR   EMBL; AB451355; BAG70169.1; -; mRNA.
DR   EMBL; AC008610; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; AC104115; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; CH471165; EAW53759.1; -; Genomic_DNA.
DR   EMBL; CH471165; EAW53757.1; -; Genomic_DNA.
DR   EMBL; CH471165; EAW53758.1; -; Genomic_DNA.
DR   EMBL; CH471165; EAW53762.1; -; Genomic_DNA.
DR   EMBL; BC032539; AAH32539.1; -; mRNA.
DR   CCDS; CCDS43409.1; -. [P45984-2]
DR   CCDS; CCDS43410.1; -. [P45984-3]
DR   CCDS; CCDS4453.1; -. [P45984-1]
DR   CCDS; CCDS4454.1; -. [P45984-4]
DR   CCDS; CCDS47356.1; -. [P45984-5]
DR   PIR; A55480; A55480.
DR   PIR; S71102; S71102.
DR   RefSeq; NP_001128516.1; NM_001135044.1. [P45984-5]
DR   RefSeq; NP_001295173.1; NM_001308244.1.
DR   RefSeq; NP_002743.3; NM_002752.4. [P45984-1]
DR   RefSeq; NP_620707.1; NM_139068.2. [P45984-2]
DR   RefSeq; NP_620708.1; NM_139069.2. [P45984-3]
DR   RefSeq; NP_620709.1; NM_139070.2. [P45984-4]
DR   RefSeq; XP_006714954.1; XM_006714891.2. [P45984-1]
DR   RefSeq; XP_016865127.1; XM_017009638.1. [P45984-4]
DR   RefSeq; XP_016865130.1; XM_017009641.1. [P45984-2]
DR   UniGene; Hs.484371; -.
DR   PDB; 3E7O; X-ray; 2.14 A; A/B=7-362.
DR   PDB; 3NPC; X-ray; 2.35 A; A/B=1-364.
DR   PDBsum; 3E7O; -.
DR   PDBsum; 3NPC; -.
DR   ProteinModelPortal; P45984; -.
DR   SMR; P45984; -.
DR   BioGrid; 111587; 112.
DR   DIP; DIP-270N; -.
DR   DIP; DIP-281N; -.
DR   IntAct; P45984; 82.
DR   MINT; MINT-1400230; -.
DR   STRING; 9606.ENSP00000389338; -.
DR   BindingDB; P45984; -.
DR   ChEMBL; CHEMBL4179; -.
DR   GuidetoPHARMACOLOGY; 1497; -.
DR   iPTMnet; P45984; -.
DR   PhosphoSitePlus; P45984; -.
DR   BioMuta; MAPK9; -.
DR   DMDM; 85700366; -.
DR   REPRODUCTION-2DPAGE; P45984; -.
DR   EPD; P45984; -.
DR   MaxQB; P45984; -.
DR   PaxDb; P45984; -.
DR   PeptideAtlas; P45984; -.
DR   PRIDE; P45984; -.
DR   DNASU; 5601; -.
DR   Ensembl; ENST00000343111; ENSP00000345524; ENSG00000050748. [P45984-3]
DR   Ensembl; ENST00000393360; ENSP00000377028; ENSG00000050748. [P45984-2]
DR   Ensembl; ENST00000425491; ENSP00000397422; ENSG00000050748. [P45984-5]
DR   Ensembl; ENST00000452135; ENSP00000394560; ENSG00000050748. [P45984-1]
DR   Ensembl; ENST00000455781; ENSP00000389338; ENSG00000050748. [P45984-4]
DR   GeneID; 5601; -.
DR   KEGG; hsa:5601; -.
DR   UCSC; uc003mls.5; human. [P45984-1]
DR   CTD; 5601; -.
DR   DisGeNET; 5601; -.
DR   GeneCards; MAPK9; -.
DR   HGNC; HGNC:6886; MAPK9.
DR   HPA; CAB008910; -.
DR   MIM; 602896; gene.
DR   neXtProt; NX_P45984; -.
DR   OpenTargets; ENSG00000050748; -.
DR   PharmGKB; PA30630; -.
DR   eggNOG; KOG0665; Eukaryota.
DR   eggNOG; ENOG410XSHI; LUCA.
DR   GeneTree; ENSGT00550000074271; -.
DR   HOGENOM; HOG000233024; -.
DR   HOVERGEN; HBG014652; -.
DR   InParanoid; P45984; -.
DR   KO; K04440; -.
DR   OMA; HSIEQWK; -.
DR   OrthoDB; EOG091G09G2; -.
DR   PhylomeDB; P45984; -.
DR   TreeFam; TF105100; -.
DR   BRENDA; 2.7.11.24; 2681.
DR   Reactome; R-HSA-2559580; Oxidative Stress Induced Senescence.
DR   Reactome; R-HSA-2871796; FCERI mediated MAPK activation.
DR   Reactome; R-HSA-450321; JNK (c-Jun kinases) phosphorylation and activation mediated by activated human TAK1.
DR   Reactome; R-HSA-450341; Activation of the AP-1 family of transcription factors.
DR   SignaLink; P45984; -.
DR   SIGNOR; P45984; -.
DR   ChiTaRS; MAPK9; human.
DR   EvolutionaryTrace; P45984; -.
DR   GeneWiki; Mitogen-activated_protein_kinase_9; -.
DR   GenomeRNAi; 5601; -.
DR   PRO; PR:P45984; -.
DR   Proteomes; UP000005640; Chromosome 5.
DR   Bgee; ENSG00000050748; -.
DR   CleanEx; HS_MAPK9; -.
DR   ExpressionAtlas; P45984; baseline and differential.
DR   Genevisible; P45984; HS.
DR   GO; GO:0005737; C:cytoplasm; IBA:GO_Central.
DR   GO; GO:0005829; C:cytosol; TAS:Reactome.
DR   GO; GO:0005739; C:mitochondrion; IEA:Ensembl.
DR   GO; GO:0043005; C:neuron projection; IBA:GO_Central.
DR   GO; GO:0005654; C:nucleoplasm; TAS:Reactome.
DR   GO; GO:0005634; C:nucleus; IBA:GO_Central.
DR   GO; GO:0005524; F:ATP binding; IEA:UniProtKB-KW.
DR   GO; GO:0004705; F:JUN kinase activity; IDA:UniProtKB.
DR   GO; GO:0008134; F:transcription factor binding; IDA:UniProtKB.
DR   GO; GO:0071276; P:cellular response to cadmium ion; IMP:CAFA.
DR   GO; GO:0071310; P:cellular response to organic substance; IBA:GO_Central.
DR   GO; GO:0034614; P:cellular response to reactive oxygen species; IMP:CAFA.
DR   GO; GO:0038095; P:Fc-epsilon receptor signaling pathway; TAS:Reactome.
DR   GO; GO:0007254; P:JNK cascade; IDA:UniProtKB.
DR   GO; GO:0048666; P:neuron development; IBA:GO_Central.
DR   GO; GO:0018105; P:peptidyl-serine phosphorylation; IDA:CAFA.
DR   GO; GO:0043065; P:positive regulation of apoptotic process; IBA:GO_Central.
DR   GO; GO:2001235; P:positive regulation of apoptotic signaling pathway; IEA:Ensembl.
DR   GO; GO:0010628; P:positive regulation of gene expression; IMP:BHF-UCL.
DR   GO; GO:0010744; P:positive regulation of macrophage derived foam cell differentiation; IMP:BHF-UCL.
DR   GO; GO:0071803; P:positive regulation of podosome assembly; IEA:Ensembl.
DR   GO; GO:0061833; P:protein localization to tricellular tight junction; IEA:Ensembl.
DR   GO; GO:0006468; P:protein phosphorylation; IMP:UniProtKB.
DR   GO; GO:0042752; P:regulation of circadian rhythm; ISS:UniProtKB.
DR   GO; GO:0051090; P:regulation of sequence-specific DNA binding transcription factor activity; TAS:Reactome.
DR   GO; GO:0009612; P:response to mechanical stimulus; IBA:GO_Central.
DR   GO; GO:0006950; P:response to stress; TAS:ProtInc.
DR   GO; GO:0048511; P:rhythmic process; IEA:UniProtKB-KW.
DR   InterPro; IPR011009; Kinase-like_dom.
DR   InterPro; IPR003527; MAP_kinase_CS.
DR   InterPro; IPR008351; MAPK_JNK.
DR   InterPro; IPR000719; Prot_kinase_dom.
DR   InterPro; IPR008271; Ser/Thr_kinase_AS.
DR   Pfam; PF00069; Pkinase; 1.
DR   PRINTS; PR01772; JNKMAPKINASE.
DR   SMART; SM00220; S_TKc; 1.
DR   SUPFAM; SSF56112; SSF56112; 1.
DR   PROSITE; PS01351; MAPK; 1.
DR   PROSITE; PS50011; PROTEIN_KINASE_DOM; 1.
DR   PROSITE; PS00108; PROTEIN_KINASE_ST; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Alternative splicing; ATP-binding; Biological rhythms;
KW   Complete proteome; Cytoplasm; Kinase; Nucleotide-binding; Nucleus;
KW   Phosphoprotein; Polymorphism; Reference proteome;
KW   Serine/threonine-protein kinase; Transferase.
FT   CHAIN         1    424       Mitogen-activated protein kinase 9.
FT                                /FTId=PRO_0000186273.
FT   DOMAIN       26    321       Protein kinase. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00159}.
FT   NP_BIND      32     40       ATP. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00159}.
FT   MOTIF       183    185       TXY.
FT   ACT_SITE    151    151       Proton acceptor. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00159, ECO:0000255|PROSITE-
FT                                ProRule:PRU10027}.
FT   BINDING      55     55       ATP. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00159}.
FT   MOD_RES     183    183       Phosphothreonine; by MAP2K7.
FT                                {ECO:0000269|PubMed:11062067}.
FT   MOD_RES     185    185       Phosphotyrosine; by MAP2K4.
FT                                {ECO:0000269|PubMed:11062067}.
FT   VAR_SEQ     216    230       GELVKGCVIFQGTDH -> AEMVLHKVLFPGRDY (in
FT                                isoform Beta-1 and isoform Beta-2).
FT                                {ECO:0000303|PubMed:14702039}.
FT                                /FTId=VSP_004834.
FT   VAR_SEQ     230    242       HIDQWNKVIEQLG -> RILPRDLGPAMLS (in
FT                                isoform 5).
FT                                {ECO:0000303|PubMed:21110917}.
FT                                /FTId=VSP_041908.
FT   VAR_SEQ     243    424       Missing (in isoform 5).
FT                                {ECO:0000303|PubMed:21110917}.
FT                                /FTId=VSP_041909.
FT   VAR_SEQ     378    424       DAAVSSNATPSQSSSINDISSMSTEQTLASDTDSSLDASTG
FT                                PLEGCR -> AQMQQ (in isoform Alpha-1 and
FT                                isoform Beta-1). {ECO:0000305}.
FT                                /FTId=VSP_004835.
FT   VARIANT      13     13       V -> M (in a colorectal adenocarcinoma
FT                                sample; somatic mutation).
FT                                {ECO:0000269|PubMed:17344846}.
FT                                /FTId=VAR_042260.
FT   VARIANT      56     56       K -> N (in a head & Neck squamous cell
FT                                carcinoma sample; somatic mutation).
FT                                {ECO:0000269|PubMed:17344846}.
FT                                /FTId=VAR_042261.
FT   VARIANT     246    246       A -> T (in dbSNP:rs35421153).
FT                                {ECO:0000269|PubMed:17344846}.
FT                                /FTId=VAR_042262.
FT   VARIANT     268    268       G -> A (in dbSNP:rs35693958).
FT                                {ECO:0000269|Ref.7}.
FT                                /FTId=VAR_025175.
FT   VARIANT     366    366       R -> I (in dbSNP:rs55736180).
FT                                {ECO:0000269|PubMed:17344846}.
FT                                /FTId=VAR_042263.
FT   CONFLICT     51     51       N -> S (in Ref. 1; AAA56831 and 3;
FT                                AAC50606/AAC50608/AAC50609).
FT                                {ECO:0000305}.
FT   CONFLICT    377    377       S -> P (in Ref. 2; AAA74740).
FT                                {ECO:0000305}.
FT   STRAND       10     15       {ECO:0000244|PDB:3E7O}.
FT   STRAND       18     23       {ECO:0000244|PDB:3E7O}.
FT   STRAND       26     33       {ECO:0000244|PDB:3E7O}.
FT   STRAND       38     45       {ECO:0000244|PDB:3E7O}.
FT   TURN         46     49       {ECO:0000244|PDB:3E7O}.
FT   STRAND       50     58       {ECO:0000244|PDB:3E7O}.
FT   HELIX        64     79       {ECO:0000244|PDB:3E7O}.
FT   STRAND       88     92       {ECO:0000244|PDB:3E7O}.
FT   TURN         98    100       {ECO:0000244|PDB:3E7O}.
FT   STRAND      105    109       {ECO:0000244|PDB:3E7O}.
FT   STRAND      112    114       {ECO:0000244|PDB:3E7O}.
FT   HELIX       115    118       {ECO:0000244|PDB:3E7O}.
FT   HELIX       125    144       {ECO:0000244|PDB:3E7O}.
FT   HELIX       154    156       {ECO:0000244|PDB:3E7O}.
FT   STRAND      157    159       {ECO:0000244|PDB:3E7O}.
FT   STRAND      165    167       {ECO:0000244|PDB:3E7O}.
FT   TURN        176    178       {ECO:0000244|PDB:3NPC}.
FT   STRAND      180    183       {ECO:0000244|PDB:3NPC}.
FT   HELIX       189    191       {ECO:0000244|PDB:3NPC}.
FT   HELIX       194    197       {ECO:0000244|PDB:3E7O}.
FT   HELIX       206    220       {ECO:0000244|PDB:3E7O}.
FT   HELIX       232    241       {ECO:0000244|PDB:3E7O}.
FT   HELIX       246    250       {ECO:0000244|PDB:3E7O}.
FT   HELIX       254    261       {ECO:0000244|PDB:3E7O}.
FT   HELIX       271    274       {ECO:0000244|PDB:3E7O}.
FT   HELIX       277    279       {ECO:0000244|PDB:3E7O}.
FT   HELIX       286    301       {ECO:0000244|PDB:3E7O}.
FT   TURN        306    308       {ECO:0000244|PDB:3NPC}.
FT   HELIX       312    316       {ECO:0000244|PDB:3E7O}.
FT   HELIX       319    322       {ECO:0000244|PDB:3E7O}.
FT   HELIX       327    330       {ECO:0000244|PDB:3NPC}.
FT   TURN        341    343       {ECO:0000244|PDB:3NPC}.
FT   HELIX       349    360       {ECO:0000244|PDB:3E7O}.
SQ   SEQUENCE   424 AA;  48139 MW;  9C15DA79981290AF CRC64;
     MSDSKCDSQF YSVQVADSTF TVLKRYQQLK PIGSGAQGIV CAAFDTVLGI NVAVKKLSRP
     FQNQTHAKRA YRELVLLKCV NHKNIISLLN VFTPQKTLEE FQDVYLVMEL MDANLCQVIH
     MELDHERMSY LLYQMLCGIK HLHSAGIIHR DLKPSNIVVK SDCTLKILDF GLARTACTNF
     MMTPYVVTRY YRAPEVILGM GYKENVDIWS VGCIMGELVK GCVIFQGTDH IDQWNKVIEQ
     LGTPSAEFMK KLQPTVRNYV ENRPKYPGIK FEELFPDWIF PSESERDKIK TSQARDLLSK
     MLVIDPDKRI SVDEALRHPY ITVWYDPAEA EAPPPQIYDA QLEEREHAIE EWKELIYKEV
     MDWEERSKNG VVKDQPSDAA VSSNATPSQS SSINDISSMS TEQTLASDTD SSLDASTGPL
     EGCR
//
